Do analysts prefer HIK or INDV?

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,128, suggesting a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor HIK or INDV?

In the previous week, Hikma Pharmaceuticals and Hikma Pharmaceuticals both had 2 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat Indivior's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HCM or HIK?

Hikma Pharmaceuticals has a consensus price target of GBX 2,128, indicating a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend AGY or HIK?

Hikma Pharmaceuticals has a consensus price target of GBX 2,128, suggesting a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Allergy Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allergy Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate APH or HIK?

Hikma Pharmaceuticals has a consensus target price of GBX 2,128, indicating a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than Alliance Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alliance Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Hikma Pharmaceuticals (HIK) Competitors

GBX 1,471 +11.00 (+0.75%)

As of 12:00 PM Eastern

Compare

HIK vs. INDV, HCM, AGY, AMYT, and APH

Should you buy Hikma Pharmaceuticals stock or one of its competitors? MarketBeat compares Hikma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hikma Pharmaceuticals include Indivior (INDV), HUTCHMED (HCM), Allergy Therapeutics (AGY), Amryt Pharma (AMYT), and Alliance Pharma (APH). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Hikma Pharmaceuticals compare to Indivior?

Hikma Pharmaceuticals (LON:HIK) and Indivior (LON:INDV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,128, suggesting a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals and Hikma Pharmaceuticals both had 2 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat Indivior's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 17.3% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals has a beta of 0.643, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.13
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

Indivior has a net margin of 14.30% compared to Hikma Pharmaceuticals' net margin of 12.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Indivior	14.30%	-41.70%	2.37%

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.7%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Hikma Pharmaceuticals beats Indivior on 13 of the 17 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to HUTCHMED?

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£548.51M	2.53	-£52.98M	£53.00	3.05
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.13

HUTCHMED has a beta of 0.453, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.643, meaning that its stock price is 36% less volatile than the broader market.

HUTCHMED has a net margin of 104.77% compared to Hikma Pharmaceuticals' net margin of 12.00%. HUTCHMED's return on equity of 41.38% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	104.77%	41.38%	-5.90%
Hikma Pharmaceuticals	12.00%	15.83%	9.40%

Hikma Pharmaceuticals has a consensus price target of GBX 2,128, indicating a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HUTCHMED	Neutral
Hikma Pharmaceuticals	Positive

20.4% of HUTCHMED shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 17.3% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Allergy Therapeutics (LON:AGY) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Hikma Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allergy Therapeutics	£57.29M	9.39	-£52.59M	-£0.97	N/A
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.13

Allergy Therapeutics has a beta of 0.891, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.643, suggesting that its stock price is 36% less volatile than the broader market.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allergy Therapeutics	-85.46%	409.00%	-34.76%
Hikma Pharmaceuticals	12.00%	15.83%	9.40%

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 3.5% of Allergy Therapeutics shares are owned by insiders. Comparatively, 17.3% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Allergy Therapeutics. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Allergy Therapeutics. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat Allergy Therapeutics' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Allergy Therapeutics	Neutral
Hikma Pharmaceuticals	Positive

Hikma Pharmaceuticals has a consensus price target of GBX 2,128, suggesting a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Allergy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allergy Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Hikma Pharmaceuticals beats Allergy Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Hikma Pharmaceuticals (LON:HIK) and Amryt Pharma (LON:AMYT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Amryt Pharma's net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Amryt Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	12.00%	15.83%	9.40%
Amryt Pharma	N/A	N/A	N/A

Hikma Pharmaceuticals currently has a consensus target price of GBX 2,128, suggesting a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Hikma Pharmaceuticals is more favorable than Amryt Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amryt Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Amryt Pharma. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Amryt Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat Amryt Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hikma Pharmaceuticals	Positive
Amryt Pharma	Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.13
Amryt Pharma	£210.24M	0.00	N/A	-£33.00	N/A

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 17.3% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Hikma Pharmaceuticals beats Amryt Pharma on 13 of the 13 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

66.3% of Alliance Pharma shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 12.0% of Alliance Pharma shares are owned by company insiders. Comparatively, 17.3% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has a consensus target price of GBX 2,128, indicating a potential upside of 44.66%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than Alliance Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alliance Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Hikma Pharmaceuticals has a net margin of 12.00% compared to Alliance Pharma's net margin of -6.00%. Hikma Pharmaceuticals' return on equity of 15.83% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alliance Pharma	-6.00%	-5.04%	5.98%
Hikma Pharmaceuticals	12.00%	15.83%	9.40%

Hikma Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alliance Pharma	£183.50M	1.91	-£33.65M	-£6.20	N/A
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.13

Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.7%. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Alliance Pharma. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Alliance Pharma. Hikma Pharmaceuticals' average media sentiment score of 0.57 beat Alliance Pharma's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Alliance Pharma	Neutral
Hikma Pharmaceuticals	Positive

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.643, indicating that its share price is 36% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats Alliance Pharma on 14 of the 18 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIK vs. The Competition

Export

Metric	Hikma Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£3.16B	£2.43B	£6.44B	£2.77B
Dividend Yield	4.34%	2.95%	2.69%	6.12%
P/E Ratio	8.13	4.85	23.77	365.54
Price / Sales	0.94	1,764.22	488.50	87,173.10
Price / Cash	8.34	10.18	41.39	27.85
Price / Book	1.43	10.82	9.76	7.68
Net Income	£353.21M	£20.70B	£3.56B	£5.89B
7 Day Performance	-0.34%	0.54%	-3.19%	-0.55%
1 Month Performance	4.26%	7.31%	-0.11%	3.15%
1 Year Performance	-30.09%	16.85%	25.29%	73.57%

Hikma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIK Hikma Pharmaceuticals	3.8884 of 5 stars	GBX 1,471 +0.8%	GBX 2,128 +44.7%	-30.6%	£3.16B	£3.35B	8.13	9,100	News Coverage
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+23.8%	£1.93B	£1.40B	N/A	1,000	News Coverage Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 174 -3.3%	N/A	-23.0%	£1.50B	£548.51M	3.28	1,760	Gap Down
AGY Allergy Therapeutics	N/A	GBX 8.50 -10.5%	N/A	+30.9%	£538.27M	£57.29M	N/A	612
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	£457.11M	£210.24M	N/A	290	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HIK) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AGY, AMYT, and APH

How does Hikma Pharmaceuticals compare to Indivior?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hikma Pharmaceuticals (HIK) Competitors

HIK vs. INDV, HCM, AGY, AMYT, and APH

How does Hikma Pharmaceuticals compare to Indivior?

Do analysts prefer HIK or INDV?

Does the media favor HIK or INDV?

Do insiders and institutionals hold more shares of HIK or INDV?

Which has more risk & volatility, HIK or INDV?

Which has preferable earnings & valuation, HIK or INDV?

Is HIK or INDV more profitable?

Is HIK or INDV a better dividend stock?

Summary

How does Hikma Pharmaceuticals compare to HUTCHMED?

Which has higher earnings & valuation, HCM or HIK?

Which has more risk & volatility, HCM or HIK?

Is HCM or HIK more profitable?

Do analysts prefer HCM or HIK?

Does the media refer more to HCM or HIK?

Do institutionals and insiders believe in HCM or HIK?

Summary

How does Hikma Pharmaceuticals compare to Allergy Therapeutics?

Which has stronger earnings & valuation, AGY or HIK?

Which has more volatility and risk, AGY or HIK?

Is AGY or HIK more profitable?

Do institutionals & insiders have more ownership in AGY or HIK?

Does the media prefer AGY or HIK?

Do analysts recommend AGY or HIK?

Summary

How does Hikma Pharmaceuticals compare to Amryt Pharma?

Is HIK or AMYT more profitable?

Do analysts recommend HIK or AMYT?

Does the media prefer HIK or AMYT?

Which has preferable earnings and valuation, HIK or AMYT?

Do insiders & institutionals have more ownership in HIK or AMYT?

Summary

How does Hikma Pharmaceuticals compare to Alliance Pharma?

Do insiders & institutionals have more ownership in APH or HIK?

Do analysts rate APH or HIK?

Is APH or HIK more profitable?

Which has better valuation and earnings, APH or HIK?

Is APH or HIK a better dividend stock?

Does the media prefer APH or HIK?

Which has more risk & volatility, APH or HIK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIK vs. The Competition

Hikma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools